# Is Semaglutide (oral) Legal? FDA, DEA and WADA Status

Source: https://pepvault.app/peptides/semaglutide-oral/legal-status

Last updated: 2026-11-18

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Peptides](https://pepvault.app/peptides) [Semaglutide (oral)](https://pepvault.app/peptides/semaglutide-oral) Legal status

Legal status in the United States

# Is Semaglutide (oral) legal?

Read November 18, 2026 at FDA, DEA and WADA [Published by PepVault](https://pepvault.app/guides/how-we-research)

Semaglutide (oral) is FDA-approved (Rybelsus, Wegovy and Ozempic, first in 2019), is not a federally controlled substance, and is not named on WADA’s Prohibited List, as of November 18, 2026.

## Semaglutide (oral) at a glance

| Check | Status, read Nov 18, 2026 |
| --- | --- |
| [FDA approval](https://pepvault.app/peptides/semaglutide-oral/legal-status#ls-fda) | Approved (Rybelsus, 2019) |
| [Compounding](https://pepvault.app/peptides/semaglutide-oral/legal-status#ls-compounding) | Approved drug; not in shortage |
| [DEA schedule](https://pepvault.app/peptides/semaglutide-oral/legal-status#ls-dea) | Not controlled |
| [Sport (WADA)](https://pepvault.app/peptides/semaglutide-oral/legal-status#ls-wada) | Not named on the list |

## FDA approval

Oral semaglutide is FDA-approved, first as the Rybelsus tablet in 2019; the Wegovy tablet followed in 2025, and Ozempic tablets, a Rybelsus formulation FDA approved under the Ozempic name on January 30, 2026, are listed on Drugs@FDA under Rybelsus’s application.

- ### Rybelsus (tablet)

  Approved for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk. NDA 213051, first approved September 20, 2019.

  - [Drugs@FDA: Rybelsus, application 213051](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213051), U.S. Food and Drug Administration. Read Nov 18, 2026.
  - [Rybelsus prescribing information on DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98), National Library of Medicine (DailyMed). Read Nov 18, 2026.
- ### Wegovy (tablet)

  Approved for weight loss and keeping it off, and lowering heart risk in adults with heart disease and excess weight. NDA 218316, first approved December 22, 2025.

  - [Drugs@FDA: Wegovy tablets, application 218316](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316), U.S. Food and Drug Administration. Read Nov 18, 2026.
  - [Wegovy prescribing information on DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b), National Library of Medicine (DailyMed). Read Nov 18, 2026.
- ### Ozempic (tablet)

  Approved for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk (the same label as Rybelsus). NDA 213051, first approved January 30, 2026.

  - [Drugs@FDA: Rybelsus and Ozempic tablets, application 213051](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213051), U.S. Food and Drug Administration. Read Nov 18, 2026.
  - [Ozempic tablets and Rybelsus prescribing information on DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98), National Library of Medicine (DailyMed). Read Nov 18, 2026.

The source: “change the name of the product from Rybelsus (formulation R2) to Ozempic (semaglutide) tablets”

- [Drugs@FDA: Rybelsus, application 213051](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213051), U.S. Food and Drug Administration. Read Nov 18, 2026.
- [FDA supplement approval letter, NDA 213051/S-030: Ozempic (semaglutide) tablets and Rybelsus (semaglutide) tablets (January 30, 2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/213051Orig1s030ltr.pdf), U.S. Food and Drug Administration. Read Nov 18, 2026.

<!--promo-->

PepVault for iPhone

## Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=legal-status-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Compounding

Semaglutide is the active ingredient of FDA-approved drugs. FDA wrote on April 1, 2026 that tirzepatide and semaglutide appear neither on the 503B bulks list nor on its drug shortage list, and outsourcing facilities may compound from bulk only what is on that list or in shortage; on April 30, 2026 FDA proposed to keep semaglutide off the 503B bulks list, finding “no clinical need.” FDA’s conditions for pharmacies under 503A include not compounding, “regularly or in inordinate amounts”, what it calls “essentially copies” of a commercially available drug. Being a component of an FDA-approved drug product is one of the three conditions FDA’s page on bulk drug substances gives for 503A.

The source: “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.”

- [FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (content current as of April 1, 2026)](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize), U.S. Food and Drug Administration. Read Nov 18, 2026.
- [FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (April 30, 2026)](https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list), U.S. Food and Drug Administration. Read Nov 18, 2026.
- [Bulk Drug Substances Used in Compounding (content current as of March 26, 2026)](https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding), U.S. Food and Drug Administration. Read Nov 18, 2026.

## DEA schedule

It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.

- [21 CFR Part 1308, Schedules of Controlled Substances (eCFR, up to date as of November 16, 2026)](https://www.ecfr.gov/current/title-21/chapter-II/part-1308), Electronic Code of Federal Regulations. Read Nov 18, 2026.
- [Controlled Substances, Alphabetical Order (dated November 17, 2026)](https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf), Drug Enforcement Administration, Diversion Control Division. Read Nov 18, 2026.

## Sport (WADA)

The 2026 Prohibited List doesn’t name semaglutide or GLP-1 drugs, and S0, the class for unapproved substances, doesn’t reach an approved drug.

- [World Anti-Doping Code International Standard, Prohibited List 2026 (in effect from January 1, 2026)](https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf), World Anti-Doping Agency. Read Nov 18, 2026.

## What this means and doesn’t

This page reports what the agencies’ own pages said about Semaglutide (oral) in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.

It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.

## About Semaglutide (oral)

### Semaglutide (oral)

- [Semaglutide (oral) in the library](https://pepvault.app/peptides/semaglutide-oral)
- [Semaglutide (oral) dose guide](https://pepvault.app/lab/dosage/semaglutide-oral)

### Terms

- [Research use only (RUO)](https://pepvault.app/glossary/research-use-only)
- [Compounded drug](https://pepvault.app/glossary/compounded)
- [Off-label use](https://pepvault.app/glossary/off-label)

## Questions

- ### Is Semaglutide (oral) FDA approved?

  Oral semaglutide is FDA-approved, first as the Rybelsus tablet in 2019; the Wegovy tablet followed in 2025, and Ozempic tablets, a Rybelsus formulation FDA approved under the Ozempic name on January 30, 2026, are listed on Drugs@FDA under Rybelsus’s application.
- ### Is Semaglutide (oral) a controlled substance?

  It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
- ### Is Semaglutide (oral) banned in sport?

  The 2026 Prohibited List doesn’t name semaglutide or GLP-1 drugs, and S0, the class for unapproved substances, doesn’t reach an approved drug.
- ### What does FDA say about compounding Semaglutide (oral)?

  Semaglutide is the active ingredient of FDA-approved drugs. FDA wrote on April 1, 2026 that tirzepatide and semaglutide appear neither on the 503B bulks list nor on its drug shortage list, and outsourcing facilities may compound from bulk only what is on that list or in shortage; on April 30, 2026 FDA proposed to keep semaglutide off the 503B bulks list, finding “no clinical need.” FDA’s conditions for pharmacies under 503A include not compounding, “regularly or in inordinate amounts”, what it calls “essentially copies” of a commercially available drug. Being a component of an FDA-approved drug product is one of the three conditions FDA’s page on bulk drug substances gives for 503A.

## Read next

- [Semaglutide (oral) in the library](https://pepvault.app/peptides/semaglutide-oral)
- [Semaglutide (oral) dose guide](https://pepvault.app/lab/dosage/semaglutide-oral)
- [Research use only (RUO)](https://pepvault.app/glossary/research-use-only)
- [Compounded drug](https://pepvault.app/glossary/compounded)
- [Off-label use](https://pepvault.app/glossary/off-label)
- [Every compound’s legal status](https://pepvault.app/peptide-legal-status)

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=legal-status-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=legal-status-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=legal-status-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## About Semaglutide (oral)

### Semaglutide (oral)

- [Semaglutide (oral) in the library](https://pepvault.app/peptides/semaglutide-oral)
- [Semaglutide (oral) dose guide](https://pepvault.app/lab/dosage/semaglutide-oral)

### Terms

- [Research use only (RUO)](https://pepvault.app/glossary/research-use-only)
- [Compounded drug](https://pepvault.app/glossary/compounded)
- [Off-label use](https://pepvault.app/glossary/off-label)

<!--promo-->

PepVault for iPhone

## Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=legal-status-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Semaglutide (oral)

- [Semaglutide (oral) in the library](https://pepvault.app/peptides/semaglutide-oral)
- [Semaglutide (oral) dose guide](https://pepvault.app/lab/dosage/semaglutide-oral)

## Legal status

- [Every compound’s legal status](https://pepvault.app/peptide-legal-status)

## The glossary

- [Research use only (RUO)](https://pepvault.app/glossary/research-use-only)
- [Compounded drug](https://pepvault.app/glossary/compounded)
- [Off-label use](https://pepvault.app/glossary/off-label)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
